AMDL's Antibiotic Approved in China
Posted on: Friday, 17 November 2006, 12:01 CST
AMDL said Friday the China State Food and Drug Administration approved its antibiotic levofloxacin.
The antibiotic is made by AMDL's China subsidiary, Jade Pharmaceutical.
China's pharmaceutical market is undergoing tremendous growth and all signs point to a continuation of this trend, said Gary Dreher, AMDL's CEO.
Jade will manufacture levofloxacin at the Jiangxi Jade facility in the South China City of Shargro in the Jiangxi Province of China.
Levofloxacin, which is a fluoroquinolone, is used to treat various infections, including pneumonia and infections of the kidney, skin and urinary tract.
Source: United Press International
Related Articles
- AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
- AMDL, Inc. Chairman & CEO Announces Expert Opinion on China's Economic Forecast
- AMDL Inc. Announces Closing of Private Placement Senior Notes
- AMDL ELISA DR-70(R) (FDP) is Promising As Effective Cancer Detection Test
- FDA Grants AMDL Clearance to Market the AMDL-ELISA DR-70(R) (FDP) Blood Test for Monitoring Colorectal Cancer
- AMDL's First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou, China
- AMDL to Address Chinese Pharmaceutical Market With Recent Product Acquisitions
- AMDL to Present at China-America Investment Conference
- AMDL Announces Jade Pharmaceutical Files for Approval for AMDL's DR-70(R) Cancer Diagnostic Test Kit in China
Rating: 3.7 / 5 (3 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds